U.S. Markets open in 9 hrs 11 mins
  • S&P Futures

    3,793.75
    +3.25 (+0.09%)
     
  • Dow Futures

    30,809.00
    -19.00 (-0.06%)
     
  • Nasdaq Futures

    13,032.25
    +46.75 (+0.36%)
     
  • Russell 2000 Futures

    2,140.20
    -7.10 (-0.33%)
     
  • Crude Oil

    53.35
    +0.37 (+0.70%)
     
  • Gold

    1,849.10
    +8.90 (+0.48%)
     
  • Silver

    25.51
    +0.19 (+0.77%)
     
  • EUR/USD

    1.2146
    +0.0013 (+0.1093%)
     
  • 10-Yr Bond

    1.0920
    -0.0050 (-0.46%)
     
  • Vix

    23.24
    -1.10 (-4.52%)
     
  • GBP/USD

    1.3656
    +0.0022 (+0.1611%)
     
  • USD/JPY

    103.7440
    -0.1480 (-0.1425%)
     
  • BTC-USD

    35,295.67
    -598.59 (-1.67%)
     
  • CMC Crypto 200

    700.71
    +0.09 (+0.01%)
     
  • FTSE 100

    6,712.95
    -7.70 (-0.11%)
     
  • Nikkei 225

    28,476.23
    -157.27 (-0.55%)
     

What Kind Of Investors Own Most Of Cabaletta Bio, Inc. (NASDAQ:CABA)?

Simply Wall St
·5 min read

Every investor in Cabaletta Bio, Inc. (NASDAQ:CABA) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. I generally like to see some degree of insider ownership, even if only a little. As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.

With a market capitalization of US$278m, Cabaletta Bio is a small cap stock, so it might not be well known by many institutional investors. Taking a look at our data on the ownership groups (below), it seems that institutional investors have bought into the company. Let's take a closer look to see what the different types of shareholders can tell us about Cabaletta Bio.

View our latest analysis for Cabaletta Bio

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Cabaletta Bio?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

As you can see, institutional investors have a fair amount of stake in Cabaletta Bio. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Cabaletta Bio's earnings history below. Of course, the future is what really matters.

earnings-and-revenue-growth
earnings-and-revenue-growth

It would appear that 36% of Cabaletta Bio shares are controlled by hedge funds. That worth noting, since hedge funds are often quite active investors, who may try to influence management. Many want to see value creation (and a higher share price) in the short term or medium term. 5AM Venture Management LLC is currently the largest shareholder, with 15% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 13% and 8.8%, of the shares outstanding, respectively. Additionally, the company's CEO Steven Nichtberger directly holds 4.8% of the total shares outstanding.

On looking further, we found that 52% of the shares are owned by the top 5 shareholders. In other words, these shareholders have a meaningful say in the decisions of the company.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage.

Insider Ownership Of Cabaletta Bio

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

Our most recent data indicates that insiders own a reasonable proportion of Cabaletta Bio, Inc.. Insiders own US$39m worth of shares in the US$278m company. This may suggest that the founders still own a lot of shares. You can click here to see if they have been buying or selling.

General Public Ownership

With a 13% ownership, the general public have some degree of sway over Cabaletta Bio. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

Private Equity Ownership

With a stake of 22%, private equity firms could influence the Cabaletta Bio board. Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. After some time they may look to sell and redeploy capital elsewhere.

Next Steps:

It's always worth thinking about the different groups who own shares in a company. But to understand Cabaletta Bio better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 2 warning signs with Cabaletta Bio (at least 1 which is a bit concerning) , and understanding them should be part of your investment process.

If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.